These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 35962543)

  • 1. Add-on effectiveness of methotrexate or iguratimod in patients with rheumatoid arthritis exhibiting an inadequate response to Janus kinase inhibitors: The ANSWER cohort study.
    Ebina K; Hirano T; Maeda Y; Okita Y; Etani Y; Hirao M; Yamamoto W; Hashimoto M; Murata K; Onishi A; Jinno S; Hara R; Son Y; Amuro H; Kotani T; Shiba H; Katayama M; Yamamoto K; Kumanogoh A; Okada S; Nakata K
    Mod Rheumatol; 2023 Jul; 33(4):690-699. PubMed ID: 35962543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The add-on effectiveness and safety of iguratimod in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab.
    Ebina K; Miyama A; Tsuboi H; Kaneshiro S; Nishikawa M; Owaki H; Tsuji S; Hirao M; Etani Y; Goshima A; Hashimoto J; Yoshikawa H
    Mod Rheumatol; 2019 Jul; 29(4):581-588. PubMed ID: 29882440
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical effectiveness of iguratimod based on real-world data of patients with rheumatoid arthritis.
    Mizutani S; Kodera H; Sato Y; Nanki T; Yoshida S; Yasuoka H
    Clin Rheumatol; 2021 Jan; 40(1):123-132. PubMed ID: 32506311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative Remission and Low Disease Activity Rates of Tofacitinib, Baricitinib, Upadacitinib, and Filgotinib versus Methotrexate in Patients with Disease-Modifying Antirheumatic Drug-Naive Rheumatoid Arthritis.
    Lee YH; Song GG
    Pharmacology; 2023; 108(6):589-598. PubMed ID: 37591216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iguratimod versus salazosulfapyridine in rheumatoid arthritis patients with an inadequate response to methotrexate: Adjusted with propensity score matching.
    Nozaki Y; Oribe M; Tomita D; Itami T; Hayashi S; Maeda T; Fukuda K; Kuroda R; Funahashi K; Matsubara T; Kinoshita K; Matsumura I
    Mod Rheumatol; 2023 Apr; 33(3):472-480. PubMed ID: 35695707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The three-year efficacy of iguratimod in clinical daily practice in patients with rheumatoid arthritis.
    Suto T; Yonemoto Y; Okamura K; Sakane H; Takeuchi K; Tamura Y; Kaneko T; Ayabe K; Chikuda H
    Mod Rheumatol; 2019 Sep; 29(5):775-781. PubMed ID: 30092680
    [No Abstract]   [Full Text] [Related]  

  • 7. A retrospective, longitudinal study of rheumatoid arthritis treatment patterns with Janus kinase inhibitors and other disease-modifying antirheumatic drugs in Japan.
    Kaneko Y; Sakurai M; Snijder R; Kokubo S; Kato D
    Mod Rheumatol; 2023 Apr; 33(3):448-459. PubMed ID: 35640001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the efficacy and safety of tofacitinib and upadacitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.
    Song GG; Choi SJ; Lee YH
    Int J Rheum Dis; 2019 Aug; 22(8):1563-1571. PubMed ID: 31211506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study.
    Smolen JS; Pangan AL; Emery P; Rigby W; Tanaka Y; Vargas JI; Zhang Y; Damjanov N; Friedman A; Othman AA; Camp HS; Cohen S
    Lancet; 2019 Jun; 393(10188):2303-2311. PubMed ID: 31130260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative remission rates of Janus kinase inhibitors in comparison with adalimumab in patients with active rheumatoid arthritis: a network meta-analysis.
    Lee YH; Song GG
    Z Rheumatol; 2024 Feb; 83(Suppl 1):88-96. PubMed ID: 35142908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are all JAK inhibitors for the treatment of rheumatoid arthritis equivalent? An adjusted indirect comparison of the efficacy of tofacitinib, baricitinib, upadacitinib, and filgotinib.
    Vallez-Valero L; Gasó-Gago I; Marcos-Fendian Á; Garrido-Alejos G; Riera-Magallón A; Plaza Diaz A; Martinez-Molina C; Mangues-Bafalluy MA; Corominas H
    Clin Rheumatol; 2023 Dec; 42(12):3225-3235. PubMed ID: 37831336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The addition of iguratimod can reduce methotrexate dose in rheumatoid arthritis with clinical remission.
    Yoshikawa A; Kotani T; Matsuda S; Hata K; Matsumura Y; Takeuchi T
    Mod Rheumatol; 2022 Jan; 32(1):68-73. PubMed ID: 33627038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The SMILE study: Study of long-term methotrexate and iguratimod combination therapy in early rheumatoid arthritis.
    Du F; Dai Q; Teng J; Lu L; Ye S; Ye P; Lin Z; Ding H; Dai M; Bao C;
    Chin Med J (Engl); 2024 Jul; ():. PubMed ID: 39056160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial.
    Fleischmann R; Pangan AL; Song IH; Mysler E; Bessette L; Peterfy C; Durez P; Ostor AJ; Li Y; Zhou Y; Othman AA; Genovese MC
    Arthritis Rheumatol; 2019 Nov; 71(11):1788-1800. PubMed ID: 31287230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: an open-label extension of a randomized, double-blind, placebo-controlled trial.
    Hara M; Ishiguro N; Katayama K; Kondo M; Sumida T; Mimori T; Soen S; Nagai K; Yamaguchi T; Yamamoto K;
    Mod Rheumatol; 2014 May; 24(3):410-8. PubMed ID: 24252050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Effectiveness and Retention Rate of Iguratimod in Japanese Rheumatoid Arthritis Patients with/without Methotrexate in Daily Medical Care.
    Inoue A; Nozaki Y; Hirooka Y; Kinoshita K; Chiba Y; Funauchi M; Matsumura I
    Life (Basel); 2020 Oct; 10(11):. PubMed ID: 33138014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discontinuation of methotrexate in rheumatoid arthritis patients achieving clinical remission by treatment with upadacitinib plus methotrexate (DOPPLER study): A study protocol for an interventional, multicenter, open-label and single-arm clinical trial with clinical, ultrasound and biomarker assessments.
    Shimizu T; Kawashiri SY; Sato S; Kawazoe Y; Kuroda S; Kawasaki R; Ito Y; Morimoto S; Yamamoto H; Kawakami A
    Medicine (Baltimore); 2022 Jan; 101(2):e28463. PubMed ID: 35029189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of the clinical use of iguratimod therapy in patients with rheumatoid arthritis.
    Okamura K; Yonemoto Y; Okura C; Kobayashi T; Takagishi K
    Mod Rheumatol; 2015 Mar; 25(2):235-40. PubMed ID: 25065917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis.
    Pope J; Sawant R; Tundia N; Du EX; Qi CZ; Song Y; Tang P; Betts KA
    Adv Ther; 2020 May; 37(5):2356-2372. PubMed ID: 32297280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iguratimod in combination with methotrexate in active rheumatoid arthritis : Therapeutic effects.
    Xia Z; Lyu J; Hou N; Song L; Li X; Liu H
    Z Rheumatol; 2016 Oct; 75(8):828-833. PubMed ID: 26508503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.